Recent Advances in the Management of Acute Lymphoblastic Leukaemia

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

(2019) Wendy Stock et al.   BLOOD

Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study

(2019) Hagop M. Kantarjian et al.   CANCER

Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia

(2019) David I. Marks et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study

(2019) Elias J. Jabbour et al.   CANCER

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

(2018) Nicola Gökbuget et al.   BLOOD

Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial

(2018) Françoise Huguet et al.   JOURNAL OF CLINICAL ONCOLOGY

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

(2018) Hagop Kantarjian et al.   LANCET ONCOLOGY

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

(2018) Jae H. Park et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

(2018) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia

(2018) Stuart E. Siegel et al.   JAMA Oncology

COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy.

(2018) Kimberly P. Dunsmore et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia

(2017) N Toft et al.   LEUKEMIA

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

(2017) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study

(2017) Hagop M Kantarjian et al.   Lancet Haematology

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

(2016) Philippe Rousselot et al.   BLOOD

CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy

(2016) Anne E. Bras et al.   BRITISH JOURNAL OF HAEMATOLOGY

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia

(2016) Sébastien Maury et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia

(2015) Y. Chalandon et al.   BLOOD

New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia

(2015) Elias Jabbour et al.   CANCER

Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study

(2015) Elias Jabbour et al.   LANCET ONCOLOGY

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

(2015) Henk M. Lokhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition

(2014) J. Irving et al.   BLOOD

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia

(2014) K. Beldjord et al.   BLOOD

Long-term outcome of a pediatric-inspired regimen used for adults aged 18–50 years with newly diagnosed acute lymphoblastic leukemia

(2014) D J DeAngelo et al.   LEUKEMIA

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

(2013) A. K. Fielding et al.   BLOOD

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

(2012) W. Haso et al.   BLOOD

Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial

(2012) Jonathan I. Sive et al.   BRITISH JOURNAL OF HAEMATOLOGY

Treatment of young patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia using increased dose of imatinib and deintensified chemotherapy before allogeneic stem cell transplantation

(2012) Josep-María Ribera et al.   BRITISH JOURNAL OF HAEMATOLOGY

Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia

(2012) Xavier Thomas   EXPERT OPINION ON INVESTIGATIONAL DRUGS

High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation

(2011) N. Gokbuget et al.   BLOOD

Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007

(2011) G. M. Dores et al.   BLOOD

Modern Therapy of Acute Lymphoblastic Leukemia

(2011) Renato Bassan et al.   JOURNAL OF CLINICAL ONCOLOGY

Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases

(2011) Sara Raponi et al.   LEUKEMIA & LYMPHOMA

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission

(2010) D. I. Marks et al.   BLOOD

Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration

(2010) Hagop M. Kantarjian et al.   CANCER

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

(2010) A. Oriol et al.   HAEMATOLOGICA

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

(2009) R. Bassan et al.   BLOOD

A population-based cytogenetic study of adults with acute lymphoblastic leukemia

(2009) A. V. Moorman et al.   BLOOD

T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993)

(2009) D. I. Marks et al.   BLOOD

Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia

(2009) S. Maury et al.   HAEMATOLOGICA

Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission

(2008) D. I. Marks et al.   BLOOD

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

(2008) W. Stock et al.   BLOOD